Teva Pharmaceutical Industries Limited
TEVA
$36.77
$0.250.69%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.81% | 2.34% | 11.40% | 3.42% | 0.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.81% | 2.34% | 11.40% | 3.42% | 0.29% |
| Cost of Revenue | -4.10% | -0.15% | -2.51% | -0.32% | -3.08% |
| Gross Profit | 2.43% | 5.01% | 25.24% | 7.21% | 3.85% |
| SG&A Expenses | 7.82% | 8.81% | 17.65% | 5.30% | 2.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -460.00% | -800.00% | -440.00% | 350.00% | 600.00% |
| Total Operating Expenses | 21.12% | 1.16% | 3.41% | 1.94% | -1.94% |
| Operating Income | -81.32% | 7.62% | 40.28% | 8.44% | 9.42% |
| Income Before Tax | -323.04% | 48.30% | 136.44% | 301.87% | 183.27% |
| Income Tax Expenses | 255.13% | -9.46% | -1,492.86% | 210.14% | -112.38% |
| Earnings from Continuing Operations | -304.26% | 67.73% | 274.55% | 211.28% | 132.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | 97.87% | -- |
| Net Income | -304.26% | 72.43% | 321.20% | 199.08% | 133.33% |
| EBIT | -81.32% | 7.62% | 40.28% | 8.44% | 9.42% |
| EBITDA | -64.37% | 5.14% | 30.38% | 5.88% | 6.41% |
| EPS Basic | -301.06% | 69.79% | 318.17% | 197.87% | 132.93% |
| Normalized Basic EPS | -108.73% | 13.99% | 34.04% | 29.03% | 1.74% |
| EPS Diluted | -306.00% | 72.22% | 313.37% | 194.87% | 132.00% |
| Normalized Diluted EPS | -108.84% | 13.86% | 31.32% | 27.15% | 0.49% |
| Average Basic Shares Outstanding | 1.57% | 1.58% | 1.41% | 1.24% | 1.24% |
| Average Diluted Shares Outstanding | 0.34% | 1.73% | 3.53% | 2.74% | 2.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |